Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 2D-29 (IGKV2D-29) encodes the variable region of the kappa light chain of immunoglobulins (antibodies)[1][2][3][5]. This variable region is critical for the diversity of antibody antigen-binding through V(D)J recombination and somatic hypermutation, contributing to the adaptive immune response[3][5]. IGKV2D-29 is a component of the immunoglobulin gene family and plays an essential role in the recognition of foreign antigens by B cells[3][5]. The gene exhibits marked polymorphism and allele distribution that varies among human populations, potentially influencing susceptibility to certain infections such as Haemophilus influenzae type b[4]. There is no evidence indicating that IGKV2D-29 itself is a direct therapeutic or druggable target, receptor, enzyme, or transporter; rather, it is a genetic element contributing to antibody diversity[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 2D-29 (IGKV2D-29).